Last updated: October 6, 2026
Polyethylene glycol 1450, or PEG 1450, is a mid-to-high molecular-weight polyethylene glycol used as a solidifying agent, carrier, lubricant, binder, coating component, ointment base, and suppository vehicle. Its market is fragmented across pharmaceutical, cosmetic, industrial, and laboratory grades. Manufacturers generally report PEG revenue by product family or molecular-weight range rather than disclosing PEG 1450 sales separately.
The commercial outlook is stable rather than high growth. Demand is supported by generic drug manufacturing, topical and rectal dosage forms, solid-dose formulation work, and contract development and manufacturing. Pricing is driven primarily by ethylene oxide and petrochemical feedstocks, plant utilization, energy costs, pharmaceutical-grade quality systems, and regional supply security.
What is polyethylene glycol 1450 and how is it used in pharmaceuticals?
PEG 1450 is a water-soluble polyether with an average molecular weight generally centered near 1,450. Commercial specifications can differ by supplier and pharmacopeial standard. The substance is commonly identified by CAS Registry Number 25322-68-3, although that CAS number covers the broader polyethylene glycol polymer family rather than a single narrowly defined molecular-weight fraction.
Typical pharmaceutical applications include:
| Application |
Function of PEG 1450 |
| Tablets and capsules |
Binder, plasticizer, lubricant, solid carrier |
| Film and sugar coatings |
Flexibility, water solubility, surface modification |
| Topical preparations |
Ointment base, humectant, solvent, viscosity modifier |
| Suppositories |
Water-soluble base and active-ingredient carrier |
| Transdermal and semisolid systems |
Solubilizer and rheology modifier |
| Drug delivery research |
Hydrophilic matrix and polymeric carrier |
PEG 1450 is selected when a formulation requires a solid or semisolid material with water miscibility and a higher melting or softening profile than lower-molecular-weight PEG grades. Lower grades such as PEG 200, PEG 400, and PEG 600 are more often used as liquid solvents or plasticizers. Higher grades such as PEG 3350 and PEG 4000 are used in laxatives, powders, granulation systems, and solid matrices.
The excipient is generally supplied as flakes, pastilles, prills, powder, or solid blocks. Particle size, hydroxyl value, water content, ethylene oxide and 1,4-dioxane residues, heavy metals, microbial quality, and molecular-weight distribution influence pharmaceutical suitability.
How large is the PEG 1450 pharmaceutical excipient market?
A standalone global revenue figure for pharmaceutical-grade PEG 1450 is not publicly disclosed by the major producers. Public market reports usually combine several PEG molecular weights or include industrial, personal-care, agricultural, and pharmaceutical applications. Supplier financial statements also aggregate PEG within broader performance-materials or specialty-chemicals reporting.
The addressable market is therefore best analyzed as a subsegment of the pharmaceutical PEG market rather than as an independently reported product category.
The commercial structure has four levels:
- Polymer production from ethylene oxide and water or related feedstock chemistry.
- Molecular-weight control and purification.
- Pharmaceutical-grade conversion, packaging, and quality release.
- Distribution through excipient suppliers, regional chemical distributors, and contract manufacturing channels.
Pharmaceutical demand is smaller than industrial PEG demand but carries higher quality, documentation, and qualification requirements. A supplier with an established pharmaceutical platform can obtain better margins than a commodity producer, although PEG 1450 remains more exposed to substitution and price competition than complex functional excipients.
What are the main market drivers for PEG 1450?
Generic drug and contract manufacturing growth
PEG 1450 is used in formulation systems that are common among generic manufacturers and contract development and manufacturing organizations. Its utility across tablets, topical products, coatings, and suppositories reduces dependence on a single branded drug.
Growth in generic manufacturing supports baseline demand, particularly in emerging pharmaceutical production centers in India, China, Southeast Asia, Latin America, and the Middle East. The main commercial constraint is that PEG 1450 is usually a small percentage of finished-product cost. Volume growth does not automatically produce equivalent revenue growth.
Expansion of semisolid and specialty dosage forms
Topical, rectal, vaginal, and controlled-release products use PEG grades as vehicles and matrix-forming materials. PEG 1450 can be useful where formulators need a balance between solid-state handling and rapid water dissolution.
Demand benefits from reformulation of difficult-to-manufacture products, but formulation selection is highly application-specific. A customer may replace PEG 1450 with PEG 1000, PEG 1500, PEG 3350, poloxamers, glycerol derivatives, waxes, carbomers, or other hydrophilic polymers.
Pharmaceutical supply-chain qualification
Pharmaceutical buyers increasingly value dual sourcing, regional inventory, audit readiness, and change-control discipline. These requirements favor suppliers that can provide:
- Certificates of analysis and traceability.
- Pharmacopeial compliance documentation.
- Elemental impurity and residual-solvent data.
- Nitrosamine and mutagenic impurity assessments where relevant.
- Stability data and controlled change notifications.
- Consistent particle-size and molecular-weight specifications.
These services raise switching costs after a customer qualifies a grade, but the barrier is operational rather than patent-based.
Which companies supply pharmaceutical-grade PEG 1450?
The competitive field includes large chemical producers, specialty excipient companies, and regional distributors. Public product portfolios often list PEG by molecular-weight series rather than identifying PEG 1450 as a separately reported business.
Relevant supplier groups include:
| Supplier group |
Competitive position |
| BASF |
Broad pharmaceutical excipient portfolio and global distribution |
| Croda |
Specialty excipient and formulation-support capabilities |
| Clariant |
PEG and specialty-chemical grades, with pharmaceutical and personal-care exposure |
| Dow |
Large-scale polyether and glycol chemistry platform |
| NOF Corporation |
Pharmaceutical and drug-delivery materials, including PEG-related technologies |
| Regional producers |
Cost competitiveness and local supply, particularly in Asia |
| Distributors |
Inventory, documentation, and smaller-lot service |
BASF, Dow, Clariant, Croda, and NOF report businesses at a level broader than PEG 1450. Their public filings do not isolate PEG 1450 revenue, margin, or capacity. The competitive advantage therefore comes from portfolio breadth, quality systems, manufacturing reliability, and customer qualification rather than from exclusive ownership of the PEG 1450 molecule.
What is the financial trajectory for PEG 1450 through 2030?
The base-case trajectory is low-to-mid single-digit annual volume growth, with revenue growth varying according to feedstock prices and product mix.
| Period |
Expected commercial condition |
Financial effect |
| 2024-2025 |
Normalization after chemical-cost and freight volatility |
Revenue growth depends heavily on price resets |
| 2026-2027 |
Continued generic and CDMO demand |
Stable volume growth; modest margin improvement for qualified grades |
| 2028-2030 |
Incremental pharmaceutical capacity and regional sourcing |
Higher demand for documented, dual-source material |
| Downside case |
Ethylene oxide inflation, oversupply, or substitution |
Price compression and inventory destocking |
| Upside case |
New topical, delivery-system, or high-specification applications |
Better mix and stronger supplier margins |
A reasonable financial model separates three variables:
Volume. Driven by production of finished dosage forms using PEG 1450 and by new customer qualifications.
Price. Driven by ethylene oxide, energy, freight, packaging, and supplier capacity utilization.
Mix. Driven by pharmaceutical-grade, low-endotoxin, low-residual, and custom particle-size products. Mix improvement has greater margin potential than volume alone.
PEG 1450 is unlikely to produce the growth profile of high-value biologic excipients, lipid nanoparticles, or advanced drug-delivery polymers. Its value is steadier: recurring demand, broad application coverage, and relatively low formulation cost.
What patents protect PEG 1450?
PEG 1450 itself is not generally protected by a current composition-of-matter patent in the manner of a pharmaceutical active ingredient. Polyethylene glycol chemistry is mature, and the polymer is widely available from multiple producers.
Patent protection may still apply to:
- Production processes and molecular-weight control.
- End-group functionalization.
- Purification and impurity-removal systems.
- PEGylated active ingredients.
- Drug-delivery systems containing PEG.
- Specific formulations using a PEG grade.
- Manufacturing equipment or packaging systems.
A PEG 1450 buyer should distinguish ownership of the base polymer from ownership of a particular PEGylated drug, formulation, or manufacturing process. The latter may have enforceable patent rights even when the excipient itself does not.
When does PEG 1450 lose exclusivity?
PEG 1450 has no single pharmaceutical exclusivity date. It is an established excipient, not an FDA-approved active ingredient with a New Chemical Entity exclusivity period.
The relevant commercial barriers are:
- Supplier qualification.
- Pharmacopeial compliance.
- Manufacturing consistency.
- Customer change-control procedures.
- Regulatory documentation.
- Capacity and regional availability.
These barriers can delay substitution but do not create statutory market exclusivity.
What is the Orange Book status of PEG 1450?
PEG 1450 is not an Orange Book-listed drug product. The FDA Orange Book covers approved drug products and related patent and exclusivity information, not excipients sold as standalone formulation materials. PEG 1450 may appear in the inactive-ingredient composition of approved products, but that does not create an Orange Book listing for the excipient itself (U.S. Food and Drug Administration, n.d.-a).
Are there Paragraph IV challenges involving PEG 1450?
Paragraph IV litigation applies to an abbreviated new drug application challenging patents listed for a reference drug. PEG 1450, as an excipient, does not have its own Paragraph IV pathway.
A generic drug containing PEG 1450 could be involved in Paragraph IV litigation if the finished product has listed patents covering formulation, dosage form, method of use, or manufacturing. The dispute would concern the drug product, not ordinary use of PEG 1450 as a commodity excipient.
Is there biosimilar risk for PEG 1450?
PEG 1450 has no direct biosimilar risk because biosimilars are biological products. PEG-related risk can arise indirectly in biologic manufacturing when a PEG-containing excipient, PEGylated active ingredient, or delivery system is used in a biologic or specialty injectable.
The more relevant issue is supply qualification. Changes in PEG molecular-weight distribution, impurities, oxidation profile, or supplier manufacturing site can trigger comparability work and regulatory review for sensitive products.
What formulation and method-of-use patents affect PEG 1450?
Patent exposure is usually located in the finished product. Relevant claims may cover:
- A defined ratio of PEG 1450 to active ingredient.
- A suppository or topical composition.
- A controlled-release matrix.
- A coating system.
- A particle-size or processing condition.
- A method for improving dissolution, stability, or bioavailability.
- A PEG-containing drug-delivery platform.
A freedom-to-operate review should search the drug product, formulation components, assignees, jurisdictions, and prosecution history. Searching only "PEG 1450" will miss patents that claim polyethylene glycol by function, molecular-weight range, or formulation role.
What manufacturing and intellectual-property barriers affect supply?
The main barriers are process control and regulatory execution rather than molecule-level exclusivity.
Manufacturers must control ethoxylation chemistry, molecular-weight distribution, residual ethylene oxide, 1,4-dioxane, water, aldehydes, metals, and microbial contamination. Pharmaceutical customers may require dedicated handling, validated cleaning, controlled packaging, and long-term stability data.
Geographic coverage also matters. North American and European customers generally prioritize pharmacopeial compliance, auditability, and supply continuity. Asian producers often compete on price and regional responsiveness. A supplier with plants in more than one region can reduce disruption risk and support dual-source strategies.
Export controls are not normally the central constraint for PEG 1450. Energy, feedstock availability, shipping costs, plant outages, and local chemical regulations have greater commercial impact.
Are licensing deals important for PEG 1450?
PEG 1450-specific licensing is not a major visible feature of the market. Commercial relationships are more often supply agreements, distribution agreements, contract manufacturing arrangements, or technology licenses for PEGylated drug-delivery systems.
Licensing value is concentrated in:
- Functionalized PEG derivatives.
- PEGylated biologics and small molecules.
- Long-acting injectable platforms.
- Nanoparticle and conjugate technologies.
- Proprietary purification and formulation processes.
The standard PEG 1450 excipient is generally purchased through qualified supply channels rather than licensed as proprietary technology.
What generic launch risks exist for PEG 1450-containing products?
PEG 1450 does not usually prevent generic entry. Generic launch risk is determined by the finished product's regulatory pathway, patent estate, bioequivalence requirements, dosage-form complexity, and manufacturing capability.
Risk is higher for:
- Modified-release products.
- Semisolids with complex microstructure.
- Suppositories requiring comparative performance testing.
- Products with narrow therapeutic windows.
- Formulations protected by composition or process claims.
- Products requiring a specific PEG molecular-weight distribution.
Risk is lower for conventional immediate-release formulations where PEG 1450 has a replaceable excipient function and multiple qualified suppliers exist.
Key Takeaways
- PEG 1450 is a mature, broadly available pharmaceutical excipient.
- Public companies do not generally report PEG 1450 revenue separately.
- Market growth is likely to be steady and volume-led, with pricing tied to feedstock and energy costs.
- The strongest commercial advantages are pharmaceutical-grade quality systems, reliable supply, documentation, and global distribution.
- PEG 1450 has no standalone Orange Book listing, FDA exclusivity period, Paragraph IV pathway, or biosimilar exposure.
- Patent risk usually concerns the finished drug, formulation, delivery system, or manufacturing process.
- Manufacturing consistency and supplier qualification create the principal practical barriers.
- Revenue upside is greater in specialized pharmaceutical grades and PEG-enabled delivery technologies than in commodity PEG 1450.
FAQs
Is PEG 1450 the same as PEG 3350?
No. Both are polyethylene glycol polymers, but they have different average molecular-weight ranges and physical properties. PEG 3350 is widely used in osmotic laxative products and higher-molecular-weight solid formulations. PEG 1450 is generally used where an intermediate solid or semisolid grade is required.
Can PEG 1450 be replaced by PEG 1500?
Potentially, but substitution requires formulation development, comparative testing, and regulatory assessment. Melting behavior, viscosity, dissolution, particle size, impurity profile, and molecular-weight distribution can differ by supplier and grade.
Is PEG 1450 suitable for injectable drugs?
Suitability depends on the specific grade, route, impurity profile, endotoxin controls, formulation, and regulatory requirements. Pharmaceutical-grade status alone does not establish suitability for parenteral use.
Does PEG 1450 create nitrosamine risk?
PEG 1450 is not itself a nitrosamine. A risk assessment may still consider raw materials, manufacturing conditions, packaging, contamination pathways, and the complete drug-product process. FDA guidance treats nitrosamine control as a product- and process-specific issue (U.S. Food and Drug Administration, n.d.-b).
Which factor most affects PEG 1450 supplier margins?
Product mix is often more important than volume. Pharmaceutical-grade material with extensive documentation, controlled particle size, validated packaging, and customer qualification can produce better margins than unqualified industrial-grade material.
References
-
BASF SE. (2025). Annual report 2024. BASF.
-
Clariant AG. (2025). Annual report 2024. Clariant.
-
Croda International Plc. (2025). Annual report and accounts 2024. Croda International.
-
Dow Inc. (2025). 2024 annual report. Dow.
-
European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.
-
U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
U.S. Food and Drug Administration. (n.d.-b). Control of nitrosamine impurities in human drugs: Guidance for industry. https://www.fda.gov/drugs/drug-safety-and-availability
-
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
